{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Endocrine&page=21",
    "query": {
      "intervention": "Endocrine",
      "page": 21
    },
    "page_size": 10
  },
  "pagination": {
    "page": 21,
    "page_size": 10,
    "total_count": 877,
    "total_pages": 88,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Endocrine&page=22&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Endocrine&page=20&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-06T16:27:29.282Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01306994",
      "title": "Study of Resting and Exercising Body Functioning in Freeman-Sheldon Syndrome and Related Conditions",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Arthrogryposis",
        "Craniofacial Abnormalities"
      ],
      "interventions": [
        {
          "name": "Lactate, Glucose, and Adenosine Triphosphate Blood Levels",
          "type": "OTHER"
        },
        {
          "name": "Physiological Stress Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Functional Enquiry Form",
          "type": "OTHER"
        },
        {
          "name": "Strength, Joint ROM, Girth and Length Measurements",
          "type": "OTHER"
        },
        {
          "name": "Study Physical Examination",
          "type": "OTHER"
        },
        {
          "name": "Observational Gait Analysis",
          "type": "OTHER"
        },
        {
          "name": "Mental Health Interview",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Freeman-Sheldon Research Group, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 0,
      "start_date": "2014-03",
      "completion_date": "2022-06",
      "has_results": false,
      "last_update_posted_date": "2022-06-06",
      "last_synced_at": "2026-11-06T16:27:29.282Z",
      "location_count": 1,
      "location_summary": "Buckhannon, West Virginia",
      "locations": [
        {
          "city": "Buckhannon",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01306994"
    },
    {
      "nct_id": "NCT00353496",
      "title": "Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endocrine Tumors"
      ],
      "interventions": [
        {
          "name": "lanreotide (Autogel formulation)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ipsen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 264,
      "start_date": "2006-06",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2025-03-05",
      "last_synced_at": "2026-11-06T16:27:29.282Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Iowa City, Iowa • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00353496"
    },
    {
      "nct_id": "NCT04632498",
      "title": "Investigating Biological Markers, Targets, and Intervention for Mood Disorders",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Major Depressive Disorder",
        "Depression",
        "Stress"
      ],
      "interventions": [
        {
          "name": "Mindfulness Based Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 61,
      "start_date": "2021-10-26",
      "completion_date": "2024-04-03",
      "has_results": false,
      "last_update_posted_date": "2024-04-04",
      "last_synced_at": "2026-11-06T16:27:29.282Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04632498"
    },
    {
      "nct_id": "NCT00525161",
      "title": "Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Suleiman Massarweh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 11,
      "start_date": "2007-10",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2015-01-26",
      "last_synced_at": "2026-11-06T16:27:29.282Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00525161"
    },
    {
      "nct_id": "NCT02513394",
      "title": "PALbociclib CoLlaborative Adjuvant Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Standard Adjuvant Endocrine Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance Foundation Trials, LLC.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5796,
      "start_date": "2015-08",
      "completion_date": "2028-12",
      "has_results": true,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-11-06T16:27:29.282Z",
      "location_count": 192,
      "location_summary": "Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 138 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02513394"
    },
    {
      "nct_id": "NCT00003517",
      "title": "Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Prostate",
        "Stage III Prostate Cancer",
        "Stage IV Prostate Cancer",
        "Recurrent Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "antineoplaston A10",
          "type": "DRUG"
        },
        {
          "name": "antineoplaston AS2-1",
          "type": "DRUG"
        },
        {
          "name": "bicalutamide",
          "type": "DRUG"
        },
        {
          "name": "flutamide",
          "type": "DRUG"
        },
        {
          "name": "leuprolide acetate",
          "type": "DRUG"
        },
        {
          "name": "alternative product therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "antiandrogen therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "biological therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "biologically based therapies",
          "type": "PROCEDURE"
        },
        {
          "name": "cancer prevention intervention",
          "type": "PROCEDURE"
        },
        {
          "name": "complementary and alternative therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "differentiation therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "endocrine therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "hormone therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Burzynski Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-07-10",
      "last_synced_at": "2026-11-06T16:27:29.282Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003517"
    },
    {
      "nct_id": "NCT06917313",
      "title": "FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer Early Stage Breast Cancer (Stage 1-3)"
      ],
      "interventions": [
        {
          "name": "Fezolinetant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 92,
      "start_date": "2025-12-05",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-06T16:27:29.282Z",
      "location_count": 2,
      "location_summary": "New Haven, Connecticut • Columbus, Ohio",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06917313"
    },
    {
      "nct_id": "NCT06897488",
      "title": "EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Adjuvant Radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "60 Years and older · Female only"
      },
      "enrollment_count": 300,
      "start_date": "2025-07-17",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-11-06T16:27:29.282Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06897488"
    },
    {
      "nct_id": "NCT02230488",
      "title": "Intensive Case Diabetes Management (ICDM) to Prevent Readmission",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "Intensive Diabetes Case Management",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2014-09",
      "completion_date": "2015-05",
      "has_results": false,
      "last_update_posted_date": "2015-06-03",
      "last_synced_at": "2026-11-06T16:27:29.282Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02230488"
    },
    {
      "nct_id": "NCT07683754",
      "title": "T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced Breast Cancer",
        "Metastatic Breast Cancer",
        "HER2 Positive",
        "HR Positive"
      ],
      "interventions": [
        {
          "name": "Trastuzumab deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Endocrine Therapy",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2026-09-18",
      "completion_date": "2030-08-28",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-11-06T16:27:29.282Z",
      "location_count": 5,
      "location_summary": "Columbia, Maryland • Las Vegas, Nevada • Nashville, Tennessee + 2 more",
      "locations": [
        {
          "city": "Columbia",
          "state": "Maryland"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "El Paso",
          "state": "Texas"
        },
        {
          "city": "New Braunfels",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07683754"
    }
  ]
}